Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Plos One|January 19, 2012
Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signallingSimon R Stockwell, Georgina Platt, S Elaine Barrie, et al.Journal of Medicinal Chemistry|December 29, 2010
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2John J Caldwell, Emma J Welsh, Cornelis Matijssen, et al.Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.Plos One|June 19, 2013
Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2M Cris Silva-Santisteban, Isaac M Westwood, Kathy Boxall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.Cancer Letters|April 29, 2025
Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkersHelen E Grimsley, Magdalena Antczak, Ian G Reddin, et al.Bioorganic & Medicinal Chemistry|October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase BIan Collins, John Caldwell, Tatiana Fonseca, et al.Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.Journal of Medicinal Chemistry|February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.Pageof 8